Frankfurt
27.06.25 | 08:02
0,081 Euro
-3,78 % -0,003
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,105 | 0,109 | 13:03 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.06. | Mauna Kea Technologies Announces Results of Its Combined General Meeting of June 5, 2025 | 321 | Business Wire | All the resolutions proposed by the Board of Directors were adopted
Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio, the multidisciplinary probe and... ► Artikel lesen | |
| 05.06. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 264 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 02.06. | Mauna Kea Technologies Announces Major AI Breakthrough with Cellvizio in Pancreatic Cystic Lesion Risk Stratification | 383 | Business Wire | Cellvizio technology combined with AI outperforms human experts in pancreatic cyst risk stratification, a major breakthrough for patient management Results build on new CLIMB study data recently... ► Artikel lesen | |
| MAUNA KEA TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 21.05. | Mauna Kea Technologies Provides Update on Safeguard Proceedings, Strategic Discussions and Operational Progress | 360 | Business Wire | Ongoing Strategic Negotiations Towards a Licensing Agreement Strong Momentum for CellTolerance: Over 1,500 Procedures Completed, New Centers of Excellence Adopting the Technology, Including a... ► Artikel lesen | |
| 20.05. | Mauna Kea Technologies Announces the Availability of Preparatory Documents for the Combined General Meeting of June 5, 2025 and the Instructions for Participation | 512 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced... ► Artikel lesen | |
| 06.05. | Mauna Kea Technologies Announces Largest Annual Pancreatic Cyst Consortium at Digestive Disease Week 2025 | 782 | Business Wire | Over 75 physicians attended educational presentations about the breakthrough impact of needle-based Confocal Laser Endomicroscopy and AI on the diagnosis and treatment of pancreatic cystic lesions... ► Artikel lesen | |
| 05.05. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 570 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 30.04. | Mauna Kea Technologies: Publication of the 2024 Annual Financial Report | 741 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced... ► Artikel lesen | |
| 28.04. | Mauna Kea Technologies Announces Another Milestone Year at Digestive Disease Week 2025 with 8 Presentations Demonstrating the Clinical Value of Cellvizio in Key Indications | 345 | Business Wire | Pancreatic cyst abstracts build on endorsement of Cellvizio by Europe's leading endoscopy society, ESGE, as a key tool for improving pancreatic cyst diagnostic accuracy AI, pancreatic cancer... ► Artikel lesen | |
| 24.04. | Mauna Kea Technologies Reports Full Year 2024 Results and Provides a Business Update | 848 | Business Wire | Commercial activities remain strong, including CellTolerance launch Recently approved safeguard proceeding yielding productive creditor and investor discussions aimed at strengthening Mauna Kea's... ► Artikel lesen | |
| 07.04. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 258 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF Listing: Euronext Growth Paris
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing:... ► Artikel lesen | |
| 01.04. | Mauna Kea Technologies Announces Entrance Into Exclusive Negotiations for a Licensing Agreement for Cellvizio in an Important Therapeutic Area With a Major Industry Player | 380 | Business Wire | The Company also confirms that it is pursuing licensing discussions in other therapeutic areas The protective framework of the safeguard proceedings enables Mauna Kea Technologies to intensify... ► Artikel lesen | |
| 31.03. | Mauna Kea Technologies Announces the Opening of a Safeguard Proceeding to Restructure Its Financial Liabilities | 605 | Business Wire | The aim of the procedure is to optimize the Company's financial structure in order to adapt it to the needs of its future growth The procedure will also provide a protective framework favorable... ► Artikel lesen | |
| 06.03. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 297 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 03.03. | Mauna Kea Technologies: Cellvizio Now Recommended in New European Society of Gastrointestinal Endoscopy Technical Guideline for Pancreatic Cyst Diagnosis | 342 | Business Wire | ESGE, Europe's leading endoscopy society, endorses Cellvizio® as a key tool for improving pancreatic cyst diagnostic accuracy, marking a major step towards broader commercial adoption
Regulatory... ► Artikel lesen | |
| 06.02. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 305 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 27.01. | Mauna Kea Technologies Announces Promising Results in New Application Combining Robotics and Cellvizio for Precision Surgery in Head and Neck Cancers | 424 | Business Wire | Cellvizio was successfully integrated into TransOral Robotic Surgery (TORS) procedures to assess peripheral mucosal margins in the larynx, oropharynx and hypopharynx Cellvizio helped identify... ► Artikel lesen | |
| 21.01. | Mauna Kea Technologies: Half-Year Liquidity Contract Statement for H2 2024 With the Brokerage Firm Gilbert Dupont | 694 | Business Wire | Regulatory News:
Under the liquidity contract between the company MAUNA KEA TECHNOLOGIES (Paris:ALMKT) and the brokerage firm Gilbert Dupont, the following resources appeared on the liquidity account... ► Artikel lesen | |
| 20.01. | Mauna Kea Technologies Secures Additional U.S. Artificial Intelligence Patent to Strengthen Endomicroscopy IP Complex | 462 | Business Wire | 13th U.S. AI patent awarded to Mauna Kea Expanded patent portfolio boosts platform value, supports strategic partnerships
Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT)... ► Artikel lesen | |
| 15.01. | Mauna Kea Technologies Reports Full Year 2024 Sales and Provides Strategic Update | 553 | Business Wire | Full Year Sales excluding licenses of €5.6m, down 9% YoY amid delayed capital sales and no revenue from JV in China Two specialized investment banks RM Global and Bucephale Finance mandated to... ► Artikel lesen |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SERNOVA BIOTHERAPEUTICS | 0,109 | +3,81 % | Sernova Biotherapeutics, Inc.: Sernova Appoints Jonathan Rigby as Interim Chair | LONDON, Ontario and BOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing its... ► Artikel lesen | |
| FAMICORD | 4,180 | 0,00 % | Original-Research: FamiCord AG (von Montega AG): Kaufen | Original-Research: FamiCord AG - von Montega AG 06.06.2025 / 17:08 CET/CEST Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group. Für den Inhalt der Mitteilung... ► Artikel lesen | |
| GERATHERM MEDICAL | 3,160 | -3,66 % | Geratherm Medical AG: GJ24 war herausfordernd, vorsichtige Prognose für GJ25; mwb research bekräftigt KAUFEN | Die Ergebnisse von Geratherm für das Geschäftsjahr 2024 zeigten einen Umsatzrückgang von 33% auf 14,0?Mio.?EUR, was in erster Linie auf deutliche Rückgänge in den Bereichen Healthcare Diagnostics und... ► Artikel lesen | |
| PLUS THERAPEUTICS | 0,318 | -13,37 % | Plus Therapeutics Expects Meaningful Revenue Contributions From CNSide Diagnostics In 2026 | WASHINGTON (dpa-AFX) - Plus Therapeutics, Inc. (PSTV), a clinical-stage pharmaceutical company, expects the revenue contributions of CNSide Diagnostics, LLC to 'become meaningful' in fiscal... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 0,745 | -2,49 % | Atossa Genetics Year-end 2024 slides: (Z)-endoxifen shows promise, expenses decline | ||
| MEDICLIN | 3,020 | -1,31 % | EQS-News: MEDICLIN AG: Ordentliche Hauptversammlung stimmt allen Beschlussvorschlägen zu | EQS-News: MEDICLIN AG
/ Schlagwort(e): Hauptversammlung
MEDICLIN AG: Ordentliche Hauptversammlung stimmt allen Beschlussvorschlägen zu
04.06.2025 / 13:27 CET/CEST
Für... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Windtree Therapeutics: Windtree Advances Lower Cost Manufacturing of PHEXXI, Evofem's Hormone-Free, On-Demand Prescription Contraceptive Gel | Windtree rapidly advancing lower cost PHEXXI manufacturing under March 2025 sourcing agreement Contract inked with outside U.S manufacturer to cut PHEXXI manufacturing costs by over 50% by end of... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 2,480 | -100,00 % | Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2025 Financial Results | Revenues increased 9% in Q4 2025 compared to Q4 2024, and 12% in FY 2025 compared to FY 2024Net loss improved 27% in Q4 2025 compared to Q4 2024, and 29% in FY 2025 compared to FY 2024EBITDA loss improved... ► Artikel lesen | |
| VERU | 0,565 | +9,51 % | Veru Inc.: Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and Preserved Lean Mass After Semaglutide Discontinuation | --During the Maintenance Period of 12 weeks after discontinuing semaglutide (GLP-1 receptor agonist), placebo group regained 43% of body weight that was previously lost during Phase 2b QUALITY study... ► Artikel lesen | |
| LIFEWARD | 0,638 | +9,68 % | Lifeward Ltd.: Administrative Law Judge Determines ReWalk Personal Exoskeleton is "Reasonable and Necessary" for Medicare Beneficiary | MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, June 24, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform... ► Artikel lesen | |
| LIGHT AI | 0,228 | +5,56 % | Light AI to Present at 25th Annual Healthcare Summit in Vancouver | ||
| EKSO BIONICS | 3,400 | -4,76 % | XFRA 23E0: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILEKSO BIONICS. NEW... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 46,900 | +0,13 % | EQS-CMS: Siemens Healthineers AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Siemens Healthineers AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b), Abs. 3 der Verordnung (EU) Nr. 596/2014, zuletzt geändert durch die Verordnung... ► Artikel lesen | |
| FRESENIUS | 42,590 | +0,95 % | Aktienmarkt: Fresenius SE & Co. KGaA-Aktie kann sich nicht behaupten (42,16 €) | Der Anteilsschein von Fresenius SE & Co. KGaA notiert am Mittwoch leichter. Die Aktie kostete zuletzt 42,16 Euro. Für Inhaber von Fresenius+Co KgaA ist der heutige Handelstag bisher nicht sonderlich... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 48,300 | +0,52 % | BERENBERG stuft FMC FRESENIUS MEDICAL CARE AG auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Fresenius Medical Care (FMC) von 55 auf 60 Euro angehoben und die Einstufung auf "Buy" belassen. Analystin Victoria Lambert... ► Artikel lesen |
MAUNA KEA TECHNOLOGIES gehört der Branche Gesundheitswesen an. Mit einer aktuellen Kursveränderung von -0,003 (-3,78 %) liegt der Kurs bei 0,081 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAUNA KEA TECHNOLOGIES finden Sie auf Wallstreet Online.